Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent
Authors:
- Ankur Kumar JindalAJAnkur Kumar Jindal
- Archan SilASArchan Sil
- Ridhima AggarwalRARidhima Aggarwal
- Keshavamurthy VinayKVKeshavamurthy Vinay
- Anuradha BishnoiABAnuradha Bishnoi
- Deepti SuriDSDeepti Suri
- Amit RawatARAmit Rawat
- Muthu Sendhil KumaranMKMuthu Sendhil Kumaran
- Biman SaikiaBSBiman Saikia
- Rashmi SarkarRSRashmi Sarkar
- Lalit GuptaLGLalit Gupta
Open Access
- 6 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 13 (2) , 60-65
Abstract
Hereditary angioedema (HAE) is an uncommon disorder characterized clinically by recurrent episodes of nonitchy subcutaneous and/or submucosal swellings. The estimated prevalence of HAE is ~ 1: 10,000 to 1: 50,000. There are no prevalence data from India, however, estimates suggest that there are 27,000 to 135,000 patients with HAE in India at present. The majority of these, however, remain undiagnosed. Replacement of plasma-derived or recombinant C1-esterase inhibitor (C1-INH) protein, administered intravenously, is the treatment of choice during the management of acute episodes of angioedema (i.e., “on-demand treatment”) and is also useful for short-term prophylaxis (STP) and long-term prophylaxis (LTP). This has been found to be effective and safe even in young children and during pregnancy. Until recently, none of the first-line treatment options were available for “on-demand treatment,” STP or LTP in India. As a result, physicians had to use fresh frozen plasma for both “on-demand treatment” and STP. For LTP, attenuated androgens (danazol or stanozolol) and/or tranexamic acid were commonly used. These drugs have been reported to be useful for LTP but are associated with a significant risk of adverse effects. Intravenous pd-C1-INH, the first-line treatment option, is now available in India. However, because there is no universal health insurance, access to pd-C1-INH is a significant challenge. HAE Society of India has developed these consensus guidelines for India and other resource-constrained settings where plasma-derived C1-INH therapy is the only available first-line treatment option for the management of HAE and diagnostic facilities are limited. These guidelines have been developed because it may not be possible for all patients to access the recommended therapy and at the recommended doses as suggested by the international guidelines. Moreover, it may not be feasible to follow the evaluation algorithm suggested by the international guidelines.Keywords
This publication has 42 references indexed in Scilit:
- Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacksAnnals of Allergy, Asthma & Immunology, 2013
- Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural historyAllergy, 2013
- Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacksAllergy and Asthma Proceedings, 2012
- C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 studyAllergy, 2011
- Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective studyOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011
- Successful C1 inhibitor short-term prophylaxis during redo mitral valve replacement in a patient with hereditary angioedemaJournal of Cardiothoracic Surgery, 2010
- Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary AngioedemaJournal of Clinical Immunology, 2010
- Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacksJournal of Allergy and Clinical Immunology, 2009
- An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedemaClinical and Experimental Immunology, 2007
- Hereditary angioedema: Its diagnostic and management perspectivesThe American Journal of Medicine, 1990